Disease-Modifying Treatments for Myasthenia Gravis

Completed

Conditions studied: Neurological Disorder, Autoimmune Diseases

In brief

This study is designed to address the evidence gaps in a real-world setting and help patients with MG choose treatments that are best suited to them. It is a prospective, multicenter observational cohort study of comparative effectiveness of MG treatments, with a patient-centered primary outcome measure, to guide clinicians, patients and payers regarding the choice of treatment options for this chronic and serious disease. Primary: To compare the effectiveness of azathioprine (AZT) and mycophenolate mofetil (MMF). Secondary: To compare the outcomes in patients receiving an adequate dose and duration of AZT or MMF over the 2-3 year study period, vs. patients not receiving adequate doses and duration of these agents

Key facts

Study ID

NCT03490539

Run by

Duke University

People needed

82

Starts

2018-05-07

Expected to finish

2021-01-31

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants eligible for inclusion in this study must fulfill all of the following criteria:
• Age ≥ 18 years of age
• Acquired autoimmune MG, with weakness and confirmed by one or more of the following:
• Elevated AChR or MuSK antibodies
• Unequivocal response to cholinesterase inhibitors
• Abnormal RNS or increased jitter (without nerve or muscle disease sufficient to produce a decrement or increased jitter)
• Patients seen initially at the participating center after January 1, 2017.
• Patients on pyridostigmine at the first evaluation at the participating center ("baseline visit") may be included if pyridostigmine was started ≤3 months before the baseline visit.
• Patients who received corticosteroids >90 days prior to baseline visit for a non-MG indication may be included. (Patients who have received corticosteroids for a non-MG indication between 31 and 90 days before baseline visit will be evaluated by the primary investigators on a case by case basis to determine if the extent and dose of corticosteroid could have impacted the course of MG or symptoms of MG.)

You may not qualify if…

• Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible participants.
• Patients with non-autoimmune MG (congenital myasthenic syndromes, drug-induced MG)
• Patients on immunosuppressive agents at the baseline visit.
• Patients who have previously received steroids for the treatment of MG.
• Patients with steroid use for a non-MG indication < 30 days prior to the baseline visit.
• Patients with previous thymectomy, IVIg or plasma exchange, or treatment with a non-steroidal immunosuppressive agent (azathioprine, mycophenolate mofetil cyclosporine, methotrexate, cyclophosphamide, tacrolimus, rituximab, or any investigational immunosuppressive agent). Patients who have outcomes measured within 24 hours after initiation of IVIg or PLEX are acceptable.

Where it is running

• Stanford University — Palo Alto, California, United States
• Unversity of Miami — Miami, Florida, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• St. Elizabeth's Medical Center — Brighton, Massachusetts, United States
• University at Buffalo, SUNY — Buffalo, New York, United States
• University of Rochester Medical Center — Rochester, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Duke University — Durham, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• University of Vermont - Larner College of Medicine — Burlington, Vermont, United States
• University of Alberta Hospital, Faculty of Medicine — Edmonton, Alberta, Canada
• London Health Sciences Centre — London, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.